Inactive Instrument

Company Arena Pharmaceuticals, Inc. Nasdaq

Equities

US0400471027

Business Summary

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

Managers

Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 21-09-30
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
Corporate Secretary - -

Company contact information

Arena Pharmaceuticals, Inc.

136 Heber Avenue Suite 204

84060-5237, Park City

+858 453 7200

http://www.arenapharm.com
address Arena Pharmaceuticals, Inc.

Sector

This company's sector is not yet available